F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds / NYT
Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.
#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda
Saturday, January 17, 2026, 8:21 am / permalink 18126 / 5 stories in 1 month
FDA rejects cancer therapy for rare post-transplant disease / Beckers
Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 2 months
NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily
oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]
#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment
Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 2 months
Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily
oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Monday, January 12, 2026, 1:21 am / permalink 17767 / 2 stories in 2 months
Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals / MedCity
Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 10, 2026, 10:21 am / permalink 17733 / 8 stories in 2 months
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints
Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months
Low-dose peanut therapy shown to protect children with peanut allergies / Medical Express
medicalxpress - Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and Montreal Children's Hospital.
#healthcare #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 5:21 pm / permalink 17464 / 3 stories in 2 months
Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily
oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety
Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months
Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss / MedCity
Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #drugdevelopment #fda
Tuesday, December 23, 2025, 3:22 pm / permalink 17254 / 36 stories in 2 months
FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily
oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months
FDA Removes Key Limitation on the Use of Real-World Evidence in Regulatory Reviews / OncoDaily
oncodaily - On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant update to its regulatory approach regarding the use of real-world evidence (RWE) in drug and medical […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda
Saturday, December 20, 2025, 4:21 pm / permalink 17179 / 13 stories in 2 months
Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily
oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]
#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment
Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 3 months
FDA approves 1st gene therapy for Wiskott-Aldrich syndrome / Beckers
Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 3 months
Zoliflodacin shows promise as single-dose treatment for gonorrhea
A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, December 13, 2025, 8:21 pm / permalink 16937 / 2 stories in 3 months
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial / American Association for Cancer Research
Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 4:21 am / permalink 16917 / 6 stories in 3 months
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial / Medical Express
medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 1:21 am / permalink 16912 / 5 stories in 3 months
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial / American Association for Cancer Research
Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Wednesday, December 10, 2025, 11:22 am / permalink 16789 / 15 stories in 3 months
Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder / MedCity
Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, December 6, 2025, 10:21 am / permalink 16661 / 2 stories in 3 months